GLP-1 Drugs Slash Up to 10% of Patients' Bone Mass

Clinical data indicates that the use of GLP-1 receptor agonists for weight loss correlates with a reduction in bone mineral density. This physiological response occurs because the skeletal system adapts to decreased mechanical loading as total body mass declines.

Secondary risks arise from nutritional deficits common in patients using these medications. Reduced caloric intake often leads to insufficient consumption of calcium, vitamin D, and protein, which are essential for maintaining skeletal integrity.

Demographic factors further exacerbate these risks, particularly among women in perimenopause or menopause. The concurrent decline in estrogen levels, which serves an osteoprotective function, increases the susceptibility of this cohort to osteopenia and osteoporosis during rapid weight loss cycles.